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1. Introduction 
The chronic obstructive pulmonary disease (COPD) encompasses two phenotypically 
related diseases, chronic bronchitis and emphysema [1-2]. Although the hallmark of COPD 
is inflammation and inability to maintain efficient gas exchange, emphysema is often 
characterized by atypical over-distension of the alveoli and permanent destruction of the 
surrounding supporting structures leading to irreversible damage to gaseous exchange. 
Statistically, it is rapidly approaching a leading cause of mortality in the United States [3], 
with a morbidity of 4.9 million [4] and mortality rate at 4.2 per 100,000 [5]. Even with a 
higher prevalence of COPD related incidences in chronic bronchitis, mortality from 
emphysema (12,790) had exceeded that of chronic bronchitis (667) in pulmonary-related 
deaths [5] making early diagnosis and treatment of emphysema an alarming and continued 
cause for concern. 
2. Pathogenesis of emphysema 
The pathogenesis of emphysema is embodied by enlargement of alveolar space, 
progressive destruction of connective tissue and loss of elasticity leading to eventual 
collapse of the small airways and destruction of pulmonary-alveolar units, all of which 
combine to limit gas exchange and airflow out of the lungs. These physical manifestations 
are usually initiated by chronic inflammation and induction of persistent oxidative stress 
mediated primarily by the neutrophil, a key innate immune cell residing in the 
conducting airways [6]. The persistent thought for the past four decades was that the 
tenuous balance between proteases and anti-proteases determined the severity of airway 
damage and alveolar enlargement, with the main protease-inhibitor, alpha1 anti-trypsin 
(AAT1) [6] severely lacking to combat the secretagogue elastase, from the chronically 
activated resident neutrophils [7-8]. Activated neutrophils also promote the secretion of 
mucus and inhibit the clearance ability of mucocilliary cilia thus adding to the severity of 
disease. 
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The role of another innate cell, the alveolar macrophage which resides in the alveolar 
region [9-10] has been demonstrated to be markedly influenced by the pro-inflammatory 
milieu and also promote the secretion of elastase [11] primarily matrix-metalloproteases 
(MMP), and key cytokines/chemokines responsible for sustaining inflammation and 
inhibition of the healing or resolution process [11]. Of all the MMP implicated, MMP-9 
was demonstrated to be markedly elevated in patients with emphysema [12-13]. Even 
though MMP-9 is capable of breaking down extra cellular matrices and cause destruction 
of the septal and alveolar walls, recent evidence has questioned its role [14-15] suggesting 
that some of the MMP may not be directly associated with the progression of disease as 
inhibiting the expression does not affect the severity in smoke-induced emphysema in 
rodents.  
A majority of recent documented emphysema cases is primarily attributed to inhalation of 
damaging stimuli such as cigarette smoke (CS) [16]. The emergent contribution of oxidants 
is integral to the development of emphysema. CS either in the form of chronic smoking or in 
the laboratory to induce experimental-emphysema in rodents, consists of both reactive 
oxygen and reactive nitrogen species, both of which are robust inducers of inflammation 
[17]. Additionally, other components of CS such as particulate matter, in itself a potent 
activator of macrophages [18-19], is able to induce the generation of macrophage-derived 
oxidants, thus adding to the persistence of a pro-inflammatory milieu. These CS- and 
macrophage-derived oxidants can contribute to the inactivation of AAT1, promote the 
activation of MMP and impair the pulmonary-alveolar units (PAU) in situ, therefore 
exaggerating the already compromised situation [20]. Another index of emphysema which 
has recently emerged is the increased pulmonary capillary endothelial cell turnover as a 
direct result of the destruction of the PAU [21], resulting in the elaboration of endothelial 
microparticle (EMP). Using stringent criteria to determine the source of PAU, the authors 
confirmed that emphysematous patients have increased circulating plasma levels of 
pulmonary capillary endothelium-derived EMP as a result of increased endothelial 
turnover. They also added that the detection of EMP in the plasma superseded any 
spirometry evidence of emphysema, thus adding an early novel albeit invasive biomarker of 
emphysema. 
There are three major causative factors for the development of emphysema; 
environmental, social and genetic predisposition. Coal miners and those working with 
silica often inhale airborne toxicants that contribute to initial oxidative stress [22]. It is the 
inability to remove these toxicants that lead to progressive inflammation and destruction 
of respiratory tissue. In addition to the anti-protease role of AAT1, recent evidence 
documenting the role of AAT1 as an anti-inflammatory protein [reviewed in 23] only 
highlights the importance of those who inherited this deficiency. The influence of 
smoking or ‘inhalation of toxicants by choice’ remains a controversial and somewhat 
contentious causative factor of emphysema. However, the combination of AAT1 
deficiency and chronic smoking or coal miners who are heavy smokers almost always 
result in the progressive development of emphysema. 
3. Presentation of COPD: Emphysema 
Chronic obstructive pulmonary disease (COPD) has significant impact on not only patients 
inflicted with the disease but also on the healthcare system under which they are taken care of.  
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Patients with severe COPD have significant physical impairment with reduction in quality 
of life and can result in death. The healthcare system requires that patients have multiple 
office visits and frequent hospitalizations on top of chronic lifelong therapy that includes 
medications and long-term oxygen treatments. Early diagnosis of COPD can help early 
management of symptoms and make lifestyle changes such as the cessation of smoking, as 
ultimately these practices are the only options to slowing the progression of disease. 
However, this disease is still underdiagnosed with only 15% of smokers diagnosed with 
COPD [24].  
Patients with emphysema can have varying degrees of symptoms ranging from few to 
chronic respiratory complaints with acute exacerbations. Some symptoms include dyspnea, 
cough, wheezing, and acute chest illnesses. Any patient with a chronic cough, dyspnea or a 
history of any exposure to risk factors such as CS, occupational dusts, chemicals and smoke 
from home or heating fuels should have the diagnosis of emphysema suspected for their 
symptoms [25]. Some patients may unknowingly restrict their own activities since 
emphysema is slowly progressive and persistent. Physical examination findings are usually 
only present in patients with severe disease which includes, over distention of the lungs in 
the stable state with the chest held near full inspiratory position at the end of normal 
expiration, and a low diaphragmatic position resulting in retraction of the lower intercostal 
spaces (Hoover’s sign) [26]. Additionally, there is decreased intensity of breath and heart 
sounds accompanied by a prolonged expiratory phase [27]. Wheezes on auscultation on 
slow or forced breathing with a prolongation of forced expiratory time may be evidence of 
airflow obstruction. Some of the frequently classically described characteristics include 
purse-lip breathing, accessory respiratory muscle usage of the neck and shoulder girdle 
muscles. Other findings may be unusual positions to relieve dyspnea such as leaning 
forward with arms outstretched (tripod position) [28], digital clubbing, dependent edema in 
the absence of right heart failure, neck vein distention and an enlarged liver due to right 
heart failure. 
Patients with suspected emphysema may present at various stages of the disease process. 
Chest radiography is usual the initial study performed or ordered but will not be diagnostic 
except in severe cases, however, is still important to exclude other lung diseases. Signs of 
hyperinflation on the chest radiograph include; rapidly tapering vascular shadows with 
increased radiolucency of the lung, a flat diaphragm and a long narrow heart shadow on 
posterior-anterior films and flat diaphragmatic contour and increased retrosternal airspace 
on a lateral radiograph (Figure 1a-b). Bullae may also be identified on a chest radiograph. 
Computed tomography (CT) is better able to characterize the involvement pattern as either 
centriacinar or panacinar. Centriacinar usually involves the upper lobes in the center of 
secondary pulmonary lobules, in contrast to panacinar with involves the lung bases and the 
entire secondary pulmonary nodule with generalized paucity of the vascular structures. CT 
has become the mainstay in evaluating patients for lung volume reduction surgery [29-30].  
Pulmonary function tests (PFTs) have become the cornerstone of the diagnostic evaluation 
of patients because these patients may be symptomatic but have no physical exam findings 
[31]. PFTs can determine the severity of the airflow obstruction and can also be used to 
follow the disease progression, with spirometry being the essential confirmatory test that 
not only stages COPD but also distinguishes the phenotype of COPD [32]. The forced 
expiratory volume in one second (FEV1) and forced vital capacity (FVC) is needed to  
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Fig. 1a. Schematic of typical anteroposterior 
 
Fig. 1b. Lateral chest radiograph findings of emphysema. 
establish the presence of obstruction, with a ratio of less than 0.70 being significant for 
obstruction [33]. The inspiratory capacity is usually decreased with tachypnea due to 
dynamic hyperinflation and increased total lung capacity, functional residual capacity and 
residual volume. The measurement of carbon monoxide diffusing capacity can help to 
establish the presence of emphysema but is not used in the routine diagnosis of COPD. 
Arterial blood gases (ABG) is used to correlate symptoms with blood oxygenation levels but 
is not needed in mild to moderate airflow obstruction. ABG is optional in moderately severe 
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airflow obstruction however, for severe disease, ABG then becomes the major monitoring 
tool once hypoxemia with hypercapnia develops. 
4. Treatment of emphysema 
The treatment of pulmonary emphysema has not only puzzled surgeons but has also 
attracted their interest throughout history. Many operations have been proposed however, it 
was not until further understanding of the physiological impairment of the disease was 
understood that appropriate surgical treatment evolved. Surgical treatment for patients on 
maximal medical therapy but remain symptomatic carries both morbidity and mortality; 
however, the operations also carry with them the hope of relief from dyspnea. Three typical 
operations performed for emphysema are bullectomy, volume reduction, and lung 
transplantation. 
4.1 Bullectomy 
Bullae are defined as emphysematous spaces larger than 1 cm in diameter in the inflated 
lung, usually demarcated from surrounding lung tissue and pathologically consists of 
enlarged airspaces covered by visceral pleural. Bullae have been characterized into three 
different types with Type I and II associated with diffuse emphysema, with type III 
representing complete loss of parenchymal architecture throughout lung fields [34]. Bullae 
in emphysematous disease is believed to arise via a ball-valve mechanism where air is 
allowed to enter the airspace but not allowed to escape with progressive enlargement of the 
airspace over time [35-36]. The enlarged space-occupying lesion leads to compression of the 
surrounding emphysematous lung tissue with preferential filling of the bullae, when 
exposed to the same negative intrapleural pressure results in continued enlargement [37-39]. 
The indication for a bullectomy is to permit expansion of the previously collapsed 
surrounding lung tissue to regain function as well as restore physiologic respiratory 
function [40]. Compression of surrounding lung tissue by bullae impairs overall gas 
exchange due to low ventilation to perfusion ratios in the compressed lung region. 
Furthermore, bullae can result in increased intra-thoracic pressures eventually resulting in 
hemodynamic dysfunction from compression of the pulmonary arterial system, decrease in 
systemic venous return, and increased expiratory airway resistance [40]. Large bullae my 
also restrict the function of the diaphragm and the thoracic chest wall muscles. Bullectomy 
would remove the space-occupying lesion, reduce expiratory airway resistance, and reduce 
dead-space ventilation that may result in overall improvement in respiratory function.  
The benefit of a bullectomy must be determined based on careful selection of individuals 
based on the size of the bullae, the degree of compression and whether underlying condition 
of compressed lung parenchyma exists [42-45]. The highest predictor for benefit from a 
bullectomy is that young individuals with large localized unilateral bullae that are 
nonventilated, nonperfused, with significant compression of surrounding lung tissue that 
has good perfusion and early emphysema [43]. Although posteroanterior and lateral 
radiographs can identify bullae, CT has become the mainstay imaging technique in 
delineating the anatomy of bullae [46]. The operative approach for bullectomy is variable 
and is dependent on the anatomic details of the bullae and specific techniques deployed by 
the surgeon in question. Single large bullae with a small pedicle may be excised using either 
a muscle-sparing thoracotomy or a video-assisted thorascopic surgery (VATS), and resected 
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with a stapler (Figure 2). In some instances, large bullae may have completely destroyed an 
entire lobe requiring lobectomy.  
 
Fig. 2. VATS stapled bullectomy. 
Mortality rates of bullectomy should range from 1 to 5%. The mortality rate of 
approximately 2.3% in well-selected patients was established more than 30 years ago by 
Fitzgerald et al with similar results in modern studies [42, 47]. Similar rates have been seen 
in patients undergoing VATS compared to thoracotomy approaches. Delayed expansion of 
the remaining lung tissue, parenchymal air leaks and pulmonary infections are some known 
post-operative complications, with air leaks being the most frequently occurring. Persistent 
air-leaks can be managed with the use of a Heimlich valve [48]. Results from bullectomies 
are difficult to analyze given that there are no prospective randomized clinical trials 
comparing medical therapy with surgery, as all previous studies were retrospective case 
series. The most recent series by Schipper et al looking at intermediate- to long-term results 
showed improvement in functional status up to 3 years after resection of giant bullae [47]. 
4.2 Lung volume reduction (LVR) 
Lung volume reduction (LVR) is similar to bullectomy, the difference being that LVR is an 
extension performed for diseases that affect the entire lung. LVR was pioneered by Otto 
Brantigan in the 1950s but was not adopted due to a high mortality rate of 18% [49]. 
Brantigan’s initial hypothesis was that the diseased portions of the lung resulted in loss of 
elasticity and that removing the most diseased portions permitted and maintained patency 
of the remaining bronchioles to improve airflow [49]. It was not until several decades later 
that Delarue et al [50] and Dahan [51] et al re-introduced the concept in patients with end-
stage emphysema. However, the role of LVR would not become popular until 1994 when 
Cooper [52] adapted Brantigan’s initial concept. The underlying pathology of end-stage 
emphysema is characterized by distended airspaces that are inadequately ventilated but 
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with continued perfusion (ventilation-perfusion mismatch) nevertheless, resection of the 
diseased portions would result in improved ventilation to other functional regions. LVR also 
serves to re-establish normal chest wall dynamics and may result in improvement in 
hemodynamic function from the lowering of intra-thoracic pressure throughout the 
respiratory cycle. 
Selection of candidates for LVR is dependent on the anatomic characteristics of the diseased 
portion of the lung with ideal candidates having heterogeneous upper-lobe involvement 
[53]. There is less dramatic improvement in candidates undergoing LVR with lower lobe 
involvement [54]. Patients being considered for LVR usually undergo scintigrams to identify 
potential targets for resection. The most important factor for success of LVR has been the 
meticulous selection of patients based on the National Emphysema Treatment Trial or NETT 
criteria [55]. Again CT has become the mainstay for characterization of possible resection 
margins. The mortality rate ranges from 0 to 7.5% with varying surgical approaches [52, 56-
58]. Multiple approaches have been used including median sternotomy, bilateral 
thoracotomies or VATS (Figure 3). All have similar results with functional improvement 
disappearing over a period of 3 to 5 years, but LVR patients continue to have a clinical 
advantage over medical treatment for those 3-5 years with substantial gains in exercise 
tolerance, freedom with oxygen therapy, and overall improvement in quality of life. The 
most significant trial, NETT, reported the results which included 1218 patients randomized 
between LVRS and medical therapy between January 1998 and July 2002 [59]. This trial 
reported a 90-day surgical mortality of 7.9% without a significant difference in surgical 
approach. Patients with upper-lobe predominant emphysema had a greater survival benefit 
from surgery while those with lower-lobe predominant emphysema demonstrated survival 
benefits from medical therapy. Based on these promising results, LVR can be performed for 
patients who are not candidates for lung transplant. 
 
Fig. 3. VATS lung volume reduction surgery for upper-lobe predominant emphysema. 
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A new technique of lung volume reduction with less morbidity and mortality compared to 
surgical LVR is bronchoscopic lung volume reduction (LVR). Bronchoscopic LVR aims to 
achieve the same goals as LVRS: improve physiologic mechanics of the chest wall and 
diaphragm, restore ventilation-perfusion matching, and improve expiratory airflow. The 
method by which this is achieved is through the use of a bronchoscope to deploy one-way 
valves, administer sealants, or apply thermal ablation to exclude diseased portions of the 
lung [60-62]. It is important to note that these techniques have not been approved by the 
Food and Drug Administration (FDA) for the treatment of severe emphysema and are 
currently utilized on experimental basis only. The most developed and well-studied of the 
bronchoscopic techniques is the one-way valve. One-way valves allow air and mucus to 
escape from the excluded portion of lung yet concomitantly excluding that portion of the 
lung from normal physiological function. [61]  Multiple valve designs have been tested, the 
largest on which was the Endobronchial Valve for Emphysema Palliation Trial (Figure 4) 
(VENT) [63-64] There was significant improvement in dyspnea, exercise capacity, and 
quality of life but not as significant as that which is seen in LVRS. [64]. Possible explanations 
for the minor improvement seen compare to LVRS have been attributed to collateral 
ventilation through incomplete lobar fissures. There were more complications of pneumonia, 
hemoptysis, and pneumothorax in the treatment group, all of which would be expected from 
an invasive procedure. [64]. The administration of sealants is far less developed and studied 
when compared to that of one-way valves, and includes the use of fibrin-thrombin mixtures to 
create a scaffold for collagen deposition by fibrblasts [65]. Preliminary studies show minor 
improvements in pulmonary function tests but no significant clinical benefits [66-67].  
 
Fig. 4. Endobronchial lung volume reduction with one-valve for lower-lobe predominant 
emphysema. 
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Thermal ablation is the least developed and studied of the bronchoscopic LVR techniques. 
The use of heated vapor to induce an inflammatory response resulting in occlusion of a 
diseased portion of lung has only been tested in feasibility studies with further exploratory 
efforts required due to small sample sizes [68]. Although bronchoscpoic LVR is an emerging 
technique, further analyses as well as long-term follow-up studies are needed. 
4.3 Lung transplantation 
Lung transplantation was originally thought to not be a feasible treatment for emphysema. 
It wasn’t until after the seminal transplantation of single lungs demonstrating significant 
improvement in symptoms, that lung transplantation became a mainstay for the end-stage 
emphysema [69-71]. Currently, the most common indication for lung transplantation is 
idiopathic diffuse emphysema and AAT1 deficiency, two criteria that account for the 
majority of lung transplants [70]. Lung transplant patients are usually so critically ill that the 
risk of death from their lung disease enables the actual lung transplant operation to appear 
quite equitable. The advantages of a lung transplant result in complete replacement of the 
diseased lung with significant improvements in symptoms [72]. There are however, 
significant disadvantages to lung transplantation including higher mortality (5 to 15%), 
lifelong immunosuppression resulting in risks of serious infection and rejection with a 
cumulative survival rate of around 50% [73-74]. 
5. Summary 
Emphysema can be a preventable and equally treatable pulmonary disease. With the advent 
of new diagnostic criteria such as the emergence of a key biomarker, circulating levels of 
EMP may lead to efficient diagnosis and preventative care. Patients with emphysema can 
present a varying array of symptoms and physical examination findings. While the majority 
of patients can be managed with medical therapy, those who continue to progress may 
require surgical intervention based on their diagnostic studies. The ideal surgical treatment 
of emphysema is dictated by a rigorous selection criteria for each of the possible 
interventions described and can dramatically improve the quality of life of individuals 
inflicted with this disease. New and innovative methods for treating crippling emphysemic 
patients who are not candidates for surgical treatments include bronchoscopic placement of 
one-way valves into diseased segments of lung tissue or airway bypass by means of 
inserting stents between bronchi and adjacent lung tissue [75-78], however, these emergent 
techniques necessitate further exploratory and long term studies. 
6. References 
[1] Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: 
a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932–94. 
[2] World Health Organization. The GOLD global strategy for the management and 
prevention of COPD: Executive summary 2006 at http://www.goldcopd.org. 
[3] http://www.cdc.gov/nchs/data/nvsr/nvsr58/nvsr58_19.pdf 
[4] http://www.cdc.gov/nchs/data/series/sr_10/sr10_249.pdf 
[5] http://www.cdc.gov/nchs/data/nvsr/nvsr58/nvsr58_19.pdf 
www.intechopen.com
 
Chronic Obstructive Pulmonary Disease – Current Concepts and Practice 
 
42
[6] Laurell CB, Eriksson S: The electrophoretic α-globulin pattern of serum in α-antitrypsin 
deficiency. Scand J Clin Invest 1963, 15:132-140. 
[7] Senior RM, Griffin GL, Mecham RP: Chemotactic activity of elastin-derived peptides. J 
Clin Invest 1980, 66:859-862. 
[8] Janoff A, Sloan B, Weinbaum G, Damiano V, Sandhaus RA, Elias J, Kimbel P: 
Experimental emphysema induced with purified human neutrophil elastase: tissue 
localization of the instilled protease. Am Rev Respir Dis 1977, 115:461-478. 
[9] Tetley T. Matrix metalloproteinases: a role in emphysema? Thorax 52: 495–497, 1997. 
[10] Hautamaki RD, Kobayashi DK, Senior RM, Shapiro SD. Requirement for macrophage 
elastase for cigarette smoke-induced emphysema in mice. Science. 1997, 
277(5334):2002-4. 
[11] Shapiro SD and Senior RM. Matrix metalloproteinases: matrix degradation and more. 
Am J Respir Cell Mol Biol 20: 1100–1102, 1999. 
[12] Finlay GA, O'Driscoll LR, Russell KJ, D'Arcy EM, Masterson JB, FitzGerald MX, 
O'Connor CM. Matrix metalloproteinase expression and production by alveolar 
macrophages in emphysema. Am J Respir Crit Care Med. 1997, 156(1):240-7. 
[13] Lim S, Roche N, Oliver BG, Mattos W, Barnes PJ, and Chung KF. Balance of matrix 
metalloprotease-9 and tissue inhibitor of metalloprotease-1 from alveolar 
macrophages in cigarette smokers. Am J Respir Crit Care Med 162: 1355–1360, 
2000. 
[14] Atkinson JJ, Lutey BA, Suzuki Y, Toennies HM, Kelley DG, Kobayashi DK, Ijem WG, 
Deslee G, Moore CH, Jacobs ME, Conradi SH, Gierada DS, Pierce RA, Betsuyaku T, 
Senior RM. The role of matrix metalloproteinase-9 in cigarette smoke-induced 
emphysema. Am J Respir Crit Care Med. 2011, 183(7):876-84. 
[15] Macnee Voekel, Norbert F. Voelkel, William MacNee. Chronic Obstructive Lung 
Disease. Eds. Macnee Voekel, William MacNee. PMPH-USA, 2008, 69-71. 
[16] Global Initiative for Chronic Obstructive Pulmonary Disease. Caverley P, Augusti A, 
Anzueto, et al, eds. Global Strategy for the Diagnosis, Management, and 
Prevention of Chronic Obstructive Pulmonary Disease. Medical Communications 
Resources; 2008. 
[17] MacNee W. Pathogenesis of chronic obstructive pulmonary disease. Proc Am Thorac 
Soc. 2005, 2:258–66. 
[18] Mehta H, Nazzal K, Sadikot RT. Cigarette smoking and innate immunity. Inflamm Res. 
2008, 57(11):497-503. 
[19] Domagala-Kulawik J. Effects of cigarette smoke on the lung and systemic immunity. J 
Physiol Pharmacol. 2008, 59 Suppl 6:19-34. 
[20] Owen CA. Proteinases and oxidants as targets in the treatment of chronic obstructive 
pulmonary disease. 2005, Proc Am Thorac Soc 2:373–85. 
[21] Gordon C, Gudi K, Krause A, Sackrowitz R, Harvey BG, Strulovici-Barel Y, Mezey JG, 
Crystal RG. Circulating endothelial microparticles as a measure of early lung 
destruction in cigarette smokers. Am J Respir Crit Care Med. 2011, 184(2):224-32. 
[22] Kuempel ED, Wheeler MW, Smith RJ, Vallyathan V, Green FH. Contributions of dust 
exposure and cigarette smoking to emphysema severity in coal miners in the 
United States. Am J Respir Crit Care Med. 2009, 180(3):257-64. 
www.intechopen.com
 
Chronic Obstructive Pulmonary Disease: Emphysema Revisited 
 
43 
[23] Janciauskiene SM, Bals R, Koczulla R, Vogelmeier C, Köhnlein T, Welte T. The 
discovery of α1-antitrypsin and its role in health and disease. Respir Med. 2011, 
105(8):1129-39. 
[24] Rennard SI, Vestbo J. COPD: the dangerous underestimate of 15%. Lancet. Apr 15 2006, 
367(9518):1216-1219. 
[25] Global Initiative for Chronic Obstructive Lung Disease strategy for the diagnosis, 
management and prevention of chronic obstructive pulmonary disease: an Asia-
Pacific perspective. Respirology. 2005, 10(1):9-17. 
[26] Lemyze M, Bart F. Hoover sign. Cmaj. 2011, 183(2):E133. 
[27] Garcia-Pachon E, Padilla-Navas I. Frequency of Hoover's sign in stable patients with 
chronic obstructive pulmonary disease. Int J Clin Pract. 2006, 60(5):514-517. 
[28] Bhatt SP, Guleria R, Luqman-Arafath TK, et al. Effect of tripod position on objective 
parameters of respiratory function in stable chronic obstructive pulmonary disease. 
Indian J Chest Dis Allied Sci. 2009, 51(2):83-85. 
[29] Klein JS, Gamsu G, Webb WR, Golden JA, Muller NL. High-resolution CT diagnosis of 
emphysema in symptomatic patients with normal chest radiographs and isolated 
low diffusing capacity. Radiology. 1992, 182(3):817-821. 
[30] Park KJ, Bergin CJ, Clausen JL. Quantitation of emphysema with three-dimensional CT 
densitometry: comparison with two-dimensional analysis, visual emphysema 
scores, and pulmonary function test results. Radiology. 1999, 211(2):541-547. 
[31] Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic 
obstructive pulmonary disease: a clinical practice guideline update from the 
American College of Physicians, American College of Chest Physicians, American 
Thoracic Society, and European Respiratory Society. Ann Intern Med. 2011, 
155(3):179-191. 
[32] Weatherall M, Marsh S, Shirtcliffe P, Williams M, Travers J, Beasley R. Quality of life 
measured by the St George's Respiratory Questionnaire and spirometry. Eur Respir 
J. 2009, 33(5):1025-1030. 
[33] Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J. 
2005, 26(2):319-338. 
[34] Reid L. The pathology of emphysema. London,: Lloyd-Luke; 1967. 
[35] F BE, Harden A, Greene DG, Cournand A, Richards DW, Jr. Pulmonary insufficiency. 
IV. A study of 16 cases of large pulmonary air cysts or bullae. Medicine (Baltimore). 
1950, 29(3):169-194. 
[36] Cooke FN, Blades B. Cystic disease of the lungs. J Thorac Surg. 1952, 23(6):546-569. 
[37] Klingman RR, Angelillo VA, DeMeester TR. Cystic and bullous lung disease. Ann 
Thorac Surg. 1991, 52(3):576-580. 
[38] Morgan MD, Denison DM, Strickland B. Value of computed tomography for selecting 
patients with bullous lung disease for surgery. Thorax. 1986, 41(11):855-862. 
[39] Morgan MD, Edwards CW, Morris J, Matthews HR. Origin and behaviour of 
emphysematous bullae. Thorax. 1989, 44(7):533-538. 
[40] De Giacomo T, Rendina EA, Venuta F, et al. Bullectomy is comparable to lung volume 
reduction in patients with end-stage emphysema. Eur J Cardiothorac Surg. 2002, 
22(3):357-362. 
[41] Ting EY, Klopstock R, Lyons HA. Mechanical properties of pulmonary cysts and bullae. 
Am Rev Respir Dis. 1963, 87:538-544. 
www.intechopen.com
 
Chronic Obstructive Pulmonary Disease – Current Concepts and Practice 
 
44
[42] FitzGerald MX, Keelan PJ, Cugell DW, Gaensler EA. Long-term results of surgery for 
bullous emphysema. J Thorac Cardiovasc Surg. 1974, 68(4):566-587. 
[43] Mineo TC, Ambrogi V, Pompeo E, Mineo D. New simple classification for operated 
bullous emphysema. J Thorac Cardiovasc Surg. 2007, 134(6):1491-1497. 
[44] Nakahara K, Nakaoka K, Ohno K, et al. Functional indications for bullectomy of giant 
bulla. Ann Thorac Surg. 1983, 35(5):480-487. 
[45] Pride NB, Barter CE, Hugh-Jones P. The ventilation of bullae and the effect of their 
removal on thoracic gas volumes and tests of over-all pulmonary function. Am Rev 
Respir Dis. 1973,107(1):83-98. 
[46] Carr DH, Pride NB. Computed tomography in pre-operative assessment of bullous 
emphysema. Clin Radiol. 1984,35(1):43-45. 
[47] Schipper PH, Meyers BF, Battafarano RJ, Guthrie TJ, Patterson GA, Cooper JD. 
Outcomes after resection of giant emphysematous bullae. Ann Thorac Surg. 2004, 
78(3):976-982; discussion 976-982. 
[48] McKenna RJ, Jr., Fischel RJ, Brenner M, Gelb AF. Use of the Heimlich valve to shorten 
hospital stay after lung reduction surgery for emphysema. Ann Thorac Surg. 1996, 
61(4):1115-1117. 
[49] Brantigan OC, Mueller E, Kress MB. A surgical approach to pulmonary emphysema. 
Am Rev Respir Dis. 1959, 80(1, Part 2):194-206. 
[50] Delarue NC, Woolf CR, Sanders DE, et al. Surgical treatment for pulmonary 
emphysema. Can J Surg. May 1977, 20(3):222-231. 
[51] Dahan M, Salerin F, Berjaud J, Renella Coll J, Gaillard J. [Value of hemodynamics in the 
surgical indications of emphysema]. Ann Chir. 1989, 43(8):669-672. 
[52] Cooper JD, Patterson GA, Sundaresan RS, et al. Results of 150 consecutive bilateral lung 
volume reduction procedures in patients with severe emphysema. J Thorac 
Cardiovasc Surg. 1996, 112(5):1319-1329. 
[53] Sciurba FC. Preoperative predictors of outcome following lung volume reduction 
surgery. Thorax. 2002, 57 Suppl 2:II47-II52. 
[54] Ciccone AM, Meyers BF, Guthrie TJ, et al. Long-term outcome of bilateral lung volume 
reduction in 250 consecutive patients with emphysema. J Thorac Cardiovasc Surg. 
2003, 125(3):513-525. 
[55] Rationale and design of the National Emphysema Treatment Trial (NETT): A 
prospective randomized trial of lung volume reduction surgery. J Thorac 
Cardiovasc Surg. 1999, 118(3):518-528. 
[56] Date H, Goto K, Souda R, et al. Bilateral lung volume reduction surgery via median 
sternotomy for severe pulmonary emphysema. Ann Thorac Surg. Apr 
1998;65(4):939-942. 
[57] McKenna RJ, Jr., Brenner M, Fischel RJ, Gelb AF. Should lung volume reduction for 
emphysema be unilateral or bilateral? J Thorac Cardiovasc Surg. 1996, 112(5):1331-
1338; discussion 1338-1339. 
[58] Miller JI, Jr., Lee RB, Mansour KA. Lung volume reduction surgery: lessons learned. 
Ann Thorac Surg. 1996, 61(5):1464-1468. 
[59] Fishman A, Martinez F, Naunheim K, et al. A randomized trial comparing lung-
volume-reduction surgery with medical therapy for severe emphysema. N Engl J 
Med. 2003, 348(21):2059-2073. 
www.intechopen.com
 
Chronic Obstructive Pulmonary Disease: Emphysema Revisited 
 
45 
[60] Herth FJ, Eberhardt R, Ingenito EP, Gompelmann D. Assessment of a novel lung sealant 
for performing endoscopic volume reduction therapy in patients with advanced 
emphysema. Expert Rev Med Devices. 2011, 8(3):307-312. 
[61] Herth FJ, Gompelmann D, Ernst A, Eberhardt R. Endoscopic lung volume reduction. 
Respiration. 2010, 79(1):5-13. 
[62] Ingenito EP, Wood DE, Utz JP. Bronchoscopic lung volume reduction in severe 
emphysema. Proc Am Thorac Soc. 2008, 5(4):454-460. 
[63] Sciurba FC, Ernst A, Herth FJ, et al. A randomized study of endobronchial valves for 
advanced emphysema. N Engl J Med. 2010, 363(13):1233-1244. 
[64] Strange C, Herth FJ, Kovitz KL, et al. Design of the Endobronchial Valve for 
Emphysema Palliation Trial (VENT): a non-surgical method of lung volume 
reduction. BMC Pulm Med. 2007, 7:10. 
[65] Ernst A, Anantham D. Endoscopic management of emphysema. Clin Chest Med. 2010, 
31(1):117-126. 
[66] Berger RL, Decamp MM, Criner GJ, Celli BR. Lung volume reduction therapies for 
advanced emphysema: an update. Chest. 2010, 138(2):407-417. 
[67] Reilly J, Washko G, Pinto-Plata V, et al. Biological lung volume reduction: a new 
bronchoscopic therapy for advanced emphysema. Chest. 2007,131(4):1108-1113. 
[68] Snell GI, Hopkins P, Westall G, Holsworth L, Carle A, Williams TJ. A feasibility and 
safety study of bronchoscopic thermal vapor ablation: a novel emphysema therapy. 
Ann Thorac Surg. 2009, 88(6):1993-1998. 
[69] Mal H, Andreassian B, Pamela F, et al. Unilateral lung transplantation in end-stage 
pulmonary emphysema. Am Rev Respir Dis. 1989, 140(3):797-802. 
[70] Pasque MK, Cooper JD, Kaiser LR, Haydock DA, Triantafillou A, Trulock EP. Improved 
technique for bilateral lung transplantation: rationale and initial clinical experience. 
Ann Thorac Surg. 1990, 49(5):785-791. 
[71] Patterson GA, Cooper JD, Goldman B, et al. Technique of successful clinical double-
lung transplantation. Ann Thorac Surg. 1988, 45(6):626-633. 
[72] Gaissert HA, Trulock EP, Cooper JD, Sundaresan RS, Patterson GA. Comparison of 
early functional results after volume reduction or lung transplantation for chronic 
obstructive pulmonary disease. J Thorac Cardiovasc Surg. 1996, 111(2):296-306. 
[73] Mendeloff EN, Meyers BF, Sundt TM, et al. Lung transplantation for pulmonary 
vascular disease. Ann Thorac Surg. 2002, 73(1):209-217. 
[74] Meyers BF, de la Morena M, Sweet SC, et al. Primary graft dysfunction and other 
selected complications of lung transplantation: A single-center experience of 983 
patients. J Thorac Cardiovasc Surg. 2005, 129(6):1421-1429. 
[75] Bhattacharyya P, Sarkar D, Nag S, Ghosh S, Roychoudhury S. Transbronchial 
decompression of emphysematous bullae: a new therapeutic approach. Eur Respir 
J. 2007, 29(5):1003-1006. 
[76] Bhattacharyya P, Bardhan S, Nag S, Mukherjee S, Verma A. Transthoracic 
decompression of emphysematous bulla: a novel experience. Indian J Chest Dis 
Allied Sci. 2011, 53(1):51-53. 
[77] Wood DE, McKenna RJ, Jr., Yusen RD, et al. A multicenter trial of an intrabronchial 
valve for treatment of severe emphysema. J Thorac Cardiovasc Surg. 2007, 
133(1):65-73. 
www.intechopen.com
 
Chronic Obstructive Pulmonary Disease – Current Concepts and Practice 
 
46
[78] Reilly J, Washko G, Pinto-Plata V, et al. Biological lung volume reduction: a new 
bronchoscopic therapy for advanced emphysema. Chest. 2007, 131(4):1108-1113. 
www.intechopen.com
Chronic Obstructive Pulmonary Disease - Current Concepts and
Practice
Edited by Dr. Kian-Chung Ong
ISBN 978-953-51-0163-5
Hard cover, 474 pages
Publisher InTech
Published online 02, March, 2012
Published in print edition March, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
A decade or so ago, many clinicians were described as having an unnecessarily 'nihilistic' view of COPD. This
has certainly changed over the years... This open access book on COPD provides a platform for scientists and
clinicians from around the world to present their knowledge of the disease and up-to-date scientific findings,
and avails the reader to a multitude of topics: from recent discoveries in the basic sciences to state-of-the-art
interventions on COPD. Management of patients with COPD challenges the whole gamut of Respiratory
Medicine - necessarily pushing frontiers in pulmonary function (and exercise) testing, radiologic imaging,
pharmaceuticals, chest physiotherapy, intensive care with respiratory therapy, bronchology and thoracic
surgery. In addition, multi-disciplinary inputs from other specialty fields such as cardiology, neuro-psychiatry,
geriatric medicine and palliative care are often necessary for the comprehensive management of COPD. The
recent progress and a multi-disciplinary approach in dealing with COPD certainly bode well for the future.
Nonetheless, the final goal and ultimate outcome is in improving the health status and survival of patients with
COPD.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Nhue L. Do and Beek Y. Chin (2012). Chronic Obstructive Pulmonary Disease: Emphysema Revisited, Chronic
Obstructive Pulmonary Disease - Current Concepts and Practice, Dr. Kian-Chung Ong (Ed.), ISBN: 978-953-
51-0163-5, InTech, Available from: http://www.intechopen.com/books/chronic-obstructive-pulmonary-disease-
current-concepts-and-practice/chronic-obstructive-pulmonary-disease-emphysema-revisited
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
